Certification to Accompany Drug, Biological Product, and Device Applications or Submissions

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
0616 ss 2-8-2021.pdf	Supporting Statement A	Uploaded 2021-02-10	Missing upstream

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
214358	BE Supplements/Amendments - ODG	Other-Guidance	Removed
214357	Original Applications - ODG	Other-Guidance	Removed
199618	Efficacy Supplements/Resubmissions - CDER and CBER	Other-Guidance	Removed
199617	Clinical Amendments to Marketing Applications - CDER and CBER	Other-Guidance	Removed
199616	New Marketing Applications/Resubmissions - CDER, CBER and CDRH	Other-Guidance	Removed
183055	Clinical Protocol Amendments (IND) - CDER and CBER	Other-Guidance	Removed
183054	Applications, amendments, resubmissions using form FDA 3674	Other-Guidance	Modified

ICR Details

OMB Control No: 0910-0616	ICR Reference No: 202011-0910-004
Status: Received in OIRA	Previous ICR Reference No: 201801-0910-004
Agency/Subagency: HHS/FDA	Agency Tracking No: CROSS CENTER
Title: Certification to Accompany Drug, Biological Product, and Device Applications or Submissions
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular	Date Submitted to OIRA: 03/03/2021

table that charts list comparision

	Requested	Previously Approved
Expiration Date	36 Months From Approved	03/31/2021
Responses	17,409	21,427
Time Burden (Hours)	5,976	7,175
Cost Burden (Dollars)	0	0

---

Abstract: This ICR collects information which will be submitted to FDA with new investigational and marketing applications/submissions and certain additional submissions to such applications for human drugs, biological products, and medical devices. It will be used by the FDA to confirm that sponsors/applicants/submitters have complied with the certification provisions in section 402(j)(5)(B) of the Public Health Service Act with regard to any applicable clinical trials referenced in the investigational or marketing applications/submissions with which the certification is submitted. FDA has developed Form FDA 3674 to facilitate the certification process for sponsors and provide FDA a means of correlating the clinical trials contained in the applications/submissions to FDA with the information contained in the ClinicalTrials.gov data bank.

---

Authorizing Statute(s): US Code: 42 USC 282 Name of Law: Public Health Service Act
   PL: Pub.L. 110 - 85 VIII Name of Law: Food and Drug Administration Amendments Act of 2007
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	85 FR 28955	05/14/2020
30-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 10104	02/18/2021
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

table that charts list of burden

IC Title	Form No.	Form Name
Applications, amendments, resubmissions using form FDA 3674	FDA 3674	Certificate of Compliance Under 42 U.S.C. 282(j)(5)(B), with Requirements of ClinicalTrials.gov Data Bank
Clinical Protocol Amendments (IND) - CDER and CBER	FDA 3674	Certification of Compliance
New Marketing Applications/Resubmissions - CDER, CBER and CDRH	FDA 3674	Certification of Compliance
Clinical Amendments to Marketing Applications - CDER and CBER	FDA 3674	Certification of Compliance
Efficacy Supplements/Resubmissions - CDER and CBER	FDA 3674	Certification of Compliance
Original Applications - ODG	FDA 3674	Certification of Compliance
BE Supplements/Amendments - ODG	FDA 3674	Certification of Compliance

---

ICR Summary of Burden

table that charts list of burden

	Total Request	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	17,409	21,427	0	-19,377	15,359	0
Annual Time Burden (Hours)	5,976	7,175	0	-6,663	5,464	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: Yes

Burden Reduction Due to: Miscellaneous Actions

Short Statement: The adjustment (decrease) in burden is due to a decrease in the overall number of research and marketing applications/submissions received by FDA since the previous submission. Additionally, we decreased the number of ICs in ROCIS from seven to one.

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     Yes

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? No

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 03/03/2021

---